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Background: Fluralaner is a novel systemic ectoparasiticide for dogs providing long-acting flea- and tick-control
after a single oral dose. The pharmacokinetics of orally administered drugs may be influenced by feeding. This study
investigated the influence of concurrent feeding on fluralaner pharmacokinetics.
Methods: Twelve fasted or fed beagles received a single oral administration of 25 mg fluralaner/kg body weight in
a chewable tablet. Plasma samples were collected at multiple post-treatment time points for fluralaner concentration
analysis. Clinical observations were performed on all dogs at regular intervals throughout the study.
Results: Fluralaner was readily absorbed in fasted and fed dogs administered at a dose of 25 mg/kg BW with a similar
mean tmax for both groups. In fed dogs, AUC and Cmax were increased compared to fasted dogs by a factor of 2.5 and
2.1 respectively. The difference in AUC and Cmax between the fed and fasted groups was statistically significant. No
adverse events were observed following oral fluralaner administration to fasted and fed dogs.
Conclusions: Fluralaner is absorbed to a considerable extent in fasted and fed dogs. Administration of fluralaner
chewable tablets with food significantly increases bioavailability.
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Fluralaner is a novel systemically administered insecticidal
and acaricidal compound that provides long-acting effi-
cacy after oral administration to dogs. Fluralaner belongs
to a new class of compounds, the isoxazolines. A field
study has shown that a single fluralaner dose administered
orally to dogs provides at least twelve weeks of flea- and
tick-control [1]. The long duration of activity offers a more
convenient treatment over monthly flea and tick control
treatments with a potential compliance advantage, redu-
cing the risk of vector-transmitted diseases.
Feeding affects gastrointestinal physiology and therefore
may influence the pharmacokinetics of a concurrently ad-
ministered drug through reduced, delayed, increased, or
accelerated absorption; in addition, there are drugs with
no food interaction [2-4]. Altered pharmacokinetics may
have an impact on the clinical activity of fluralaner [3,4].
For example, an increase in absorption in a fed animal
may lead to a prolonged period of efficacy. Administration
of fluralaner tablets at or around the time of feeding may* Correspondence: feli.walther@msd.de
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unless otherwise stated.be an option chosen by some dog owners to facilitate ad-
ministration of the chewable tablet. A drug-food effect can-
not be predicted on a scientific basis and specific studies
are required to investigate possible effects [2-4]; therefore,
this study was performed to evaluate the impact of food on
the pharmacokinetic profile of fluralaner chewable tablets.Methods
This study was conducted in compliance with the German
animal protection legislation framework and ethical
approval was obtained before the start of the study
(authorization reference 23 177-07 /G 08-4-003). Dogs
were kept indoors in pens with sealed floors and indivi-
dually housed until 3 days after tablet administration.
They had access to water ad libitum throughout the study
period and were fed a standard dog diet (Bosch Tiernahrung
GmbH&Co. KG; dry kibble food; composition: protein 21%,
fat 6%, crude fiber 7%, crude ash 6%, moisture 10%). 12
healthy beagles were allocated to either a fed or fasted study
group by sorting dogs within gender according to ascend-
ing body weight and alternately assigning dogs to a group
(Table 1).l Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Table 1 Fasted and fed dog groups for evaluation of
fluralaner pharmacokinetic parameters
Fasted group Fed group
Gender Male 4 3
Female 2 3
Body weight (kg) Mean 14.0 13.5
Range 12.2 – 16.6 12.0 – 15.6
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body weight on day 0 using chewable tablets containing
fluralaner. Chewable tablets were cut to achieve the indivi-
dual target dose. Tablets were placed on the back of the
tongue and swallowing was stimulated with a small amount
of tap water.
Both groups were fasted for 25 hours prior to flurala-
ner administration. Dogs in the fed group were offered
half the normal daily food ration 15 minutes prior to
fluralaner administration and the remaining half of the
daily food ration was offered to these dogs immediately
after administration. Dogs in the fasted group received
orally administered fluralaner chewable tablets without
feeding and remained unfed for a further 8 hours. Dogs
were observed at regular intervals for any clinical find-
ings throughout the study. The veterinary study super-
visor assessed any clinical findings for their relationship
to fluralaner treatment. All treatment-related findings
were classified as adverse events.
Blood samples for fluralaner plasma concentration deter-
mination were collected prior to tablet administration and
at 2, 4, and 8 hours, and then 1, 2, 3, 4, 7, 14, 21, 28, 42, 56,
70, 84, and 91 days after tablet administration. The blood
sampling time points were selected based on previous phar-
macokinetic data (unpublished observations), to cover initial
rapid absorption, redistribution and prolonged elimination
over 13 weeks following oral treatment. Fluralaner blood
plasma concentrations were determined using automated
solid-phase extraction coupled to liquid chromatography
with mass-spectrometry (Online-SPE – HPLC/MS/MS;
lower limit of quantification 5 ng/ml). The bioanalytical
method was validated based on regulatory guidelines [5,6].
Fluralaner pharmacokinetics evaluation was based on
the plasma concentration of the parent compound for the
area under the curve from time 0 to the last sampling time
point associated with a quantifiable concentration (91 days
after administration, AUC0-91d), maximum plasma con-
centration (Cmax) and time to Cmax (tmax). Pharmacoki-
netic parameters were calculated using noncompartmental
methods (WinNonlin 5.2.1, Pharsight, Mountain View,
California). The AUC0-91d was calculated using the linear
trapezoidal method.
The effect of food on fluralaner pharmacokinetics was
calculated by comparison of the means of AUC0-91d and
Cmax of both groups according to the following ratios:AUC0-91d(fed)/AUC0-91d(fasted) or Cmax(fed)/Cmax(fasted). Sta-
tistics (SAS® Language: Reference, Version 9.3, SAS In-
stitute Inc., Cary, NC, USA) were calculated using the
individual dog as the experimental unit.
Results and discussion
Orally administered fluralaner was readily absorbed (mean
Tmax of 1 day) in both fasted and fed dogs and was quanti-
fiable in both groups throughout the entire study period
(Figure 1). The calculated AUC0-91d ratio between the two
groups was 2.5 and the Cmax ratio was 2.1; AUC0-91d and
Cmax were significantly higher in the fed group (Table 2).
In contrast, tmax was not significantly different between
both study groups (Table 2). Many drugs that show food
interactions as increased absorption also exhibit delayed
absorption [2]. In the present study, the similarity between
fed and fasted groups in the time to reach maximum
plasma concentrations indicates that fluralaner absorption,
and thereby onset of the parasiticide effect, is not delayed
through feeding.
Food can also effect drug distribution, metabolism and
elimination [3,4]. However, the similar pattern of plasma
concentration in both groups of the present study
(Figure 1) indicates that the feeding status of the dog
has no effect on subsequent distribution, metabolism or
excretion of fluralaner.
The extent of a drug-food interaction can be affected by
the drug formulation [2,3]. However, the tablet formulation
used in the present study is equivalent to the formulation
developed for the final commercial product BravectoTM;
therefore, the results of the present study are considered to
represent the drug-food interaction for BravectoTM.
For some drugs, bioavailability is increased with an in-
crease in dietary fat content, whereas dietary fiber may re-
duce drug availability [3]. For this study, a commercially
available low-fat diet with high fiber content was used with
the expectation that this would potentially minimize the ef-
fect of the diet on fluralaner availability. However, the food
effect on fluralaner may be similar for other types of diets.
The timing of feeding relative to oral treatment may im-
pact drug-food interactions [3]. In the present study, all
fed group dogs completely consumed the initial portion of
daily food ration prior to fluralaner administration and
rapidly consumed the remaining daily ration offered after
administration. Therefore, the recommended administra-
tion for BravectoTM chewable tablets is at or around the
time of feeding.
Co-administration of a drug with food might reduce
or increase inter-individual variability in drug plasma
concentrations [3]. In the present study, both, the AUC
and Cmax, showed lower standard deviations in the fed
group, indicating less pronounced individual variability
and providing an additional reason to recommend co-
administration with food.
Figure 1 Mean fluralaner plasma concentration (± standard deviation) following oral administration (25 mg/kg) to fasted or fed dogs.
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pharmacokinetics of feeding quantities smaller than the
full daily ration at the time of treatment; however, it is
possible that co-administration with smaller quantities
of food will also increase fluralaner bioavailability.
In the present study, no clinical findings were ob-
served in dogs in either group post treatment indicating
an adverse event; therefore, the increase in fluralaner
bioavailability is not thought to be associated with an in-
creased risk of toxicity, as has been suggested for other
compounds [4]. In support of this, fluralaner safety
following high dose oral administration was thor-
oughly investigated, confirming a high safety margin
for fluralaner [7].
Conclusions
Fluralaner is a novel potent insecticide and acaricide
with a longer duration of action in dogs than currentlyTable 2 Fluralaner pharmacokinetic parameters following ora
Parameter Unit Fasted group
Mean ± SD
(range)
Cmax (ng/mL) 1591 ± 708
(1037–2683)
tmax (day) 1.3 ± 1.2
(0.17 – 3.00)
AUC0-91d (day*ng/mL) 31369 ± 20654
(14316 – 63557)
SD: Standard deviation.available commercial products applied orally or topically
[1]. Fluralaner is formulated as an oral chewable tablet
and some dog owners may choose to facilitate adminis-
tration by dosing at or around the time of feeding. The
results of this study show that fluralaner is rapidly
absorbed in both fasted and fed dogs and is detectable in
plasma for more than 12 weeks in both groups. Oral ad-
ministration of fluralaner to dogs together with their full
ration of food resulted in total drug exposure over the
subsequent 91 days that was 2.5 times greater than in
dogs treated while fasting. Similarly, the maximum
plasma concentration was 2.1 times higher in fully fed
dogs compared with fasted dogs.
Administration at the time of feeding more than dou-
bles fluralaner bioavailability and this difference is statis-
tically significant. For these reasons, administration of
fluralaner chewable tablets at or around the time of
feeding is recommended.l administration (25 mg/kg) to fasted or fed dogs
Fed group P value Ratio (fed/fasted)
Mean ± SD
(range)
3377 ± 669 0.0015 2.1
(2325 – 4326)
1.4 ± 1.3 0.8096 -
(0.33 – 4.00)
78785 ± 11440 0.0022 2.5
(60862 – 91854)
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